Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors-Reference-Cited by-同舟云学术

Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors

Published:2020-06 Issue: Volume:99 Page:103851
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Bahekar Rajesh,Panchal Nandini,Soman Shubhangi,Desai Jigar,Patel Dipam,Argade Anil,Gite Archana,Gite Sanjay,Patel Bhaumin,Kumar Jeevan,S Sachchidanand,Patel Harilal,Sundar Rajesh,Chatterjee Abhijit,Mahapatra Jogeswar,Patel Hoshang,Ghoshdastidar Krishnarup,Bandyopadhyay Debdutta,Desai Ranjit C.

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference37 articles.

1. Novel phosphoinositide 3-kinase δ, γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis;Boyle;J. Pharmacol. Exp. Thera.,2014

2. Challenges in the treatment of Rheumatoid Arthritis;Conigliaro;Autoimmun. Rev.,2019

3. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

4. Interferons pen the JAK-STAT pathway;Schindler;Seminar Cell Dev. Biol.,2008

5. Dynamics and non-canonical aspects of JAK/STAT signaling;Mohr;Eur. J. Cell Biol.,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis;Bioorganic Chemistry;2024-08

2. Design, Synthesis and Bioactivity Study of Marine Alkaloid Neobacillamide—A Derivatives;Journal of Ocean University of China;2023-05-13

3. Machine Learning‐Enabled Virtual Screening with Multiple Protein Structures toward the Discovery of Novel JAK3 Inhibitors: Integration of Molecular Docking, Pharmacophore, and Naïve Bayesian Classification;Advanced Theory and Simulations;2023-05-07

4. ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma;Onco;2022-10-14

5. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor;Bioorganic & Medicinal Chemistry Letters;2022-06